These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 3893032

  • 21. Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha.
    Larsson C, Stålhammar-Carlemalm M, Lindahl G.
    Infect Immun; 1996 Sep; 64(9):3518-23. PubMed ID: 8751893
    [Abstract] [Full Text] [Related]

  • 22. Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens.
    Lancefield RC, McCarty M, Everly WN.
    J Exp Med; 1975 Jul 01; 142(1):165-79. PubMed ID: 1097573
    [Abstract] [Full Text] [Related]

  • 23. Complete and incomplete Ibc protein fraction in group B streptococci.
    Bevanger L, Maeland JA.
    Acta Pathol Microbiol Scand B; 1979 Feb 01; 87B(1):51-4. PubMed ID: 107722
    [Abstract] [Full Text] [Related]

  • 24. Monoclonal antibodies targeting different cell wall antigens of group B streptococcus mediate protection in both Fc-dependent and independent manner.
    Senn BM, Visram Z, Meinke AL, Neubauer C, Gelbmann D, Sinzinger J, Hanner M, Lundberg U, Boisvert H, Reinscheid D, von Gabain A, Nagy E.
    Vaccine; 2011 May 31; 29(24):4116-24. PubMed ID: 21496467
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Nonimmunodominant regions are effective as building blocks in a streptococcal fusion protein vaccine.
    Stålhammar-Carlemalm M, Waldemarsson J, Johnsson E, Areschoug T, Lindahl G.
    Cell Host Microbe; 2007 Dec 13; 2(6):427-34. PubMed ID: 18078694
    [Abstract] [Full Text] [Related]

  • 27. Protective efficacy of hybridoma type-specific antibody against experimental infection with group-B Streptococcus.
    Shigeoka AO, Pincus SH, Rote NS, Hill HR.
    J Infect Dis; 1984 Mar 13; 149(3):363-72. PubMed ID: 6371154
    [Abstract] [Full Text] [Related]

  • 28. Deletion of repeats in the alpha C protein enhances the pathogenicity of group B streptococci in immune mice.
    Gravekamp C, Rosner B, Madoff LC.
    Infect Immun; 1998 Sep 13; 66(9):4347-54. PubMed ID: 9712787
    [Abstract] [Full Text] [Related]

  • 29. Characterization of the alpha antigen of the c proteins of group B streptococci (GBS) using a murine monoclonal antibody.
    Bevanger L, Iversen OJ, Naess AI.
    APMIS; 1992 Jan 13; 100(1):57-62. PubMed ID: 1536721
    [Abstract] [Full Text] [Related]

  • 30. A monoclonal antibody identifies a protective C-protein alpha-antigen epitope in group B streptococci.
    Madoff LC, Michel JL, Kasper DL.
    Infect Immun; 1991 Jan 13; 59(1):204-10. PubMed ID: 1702759
    [Abstract] [Full Text] [Related]

  • 31. A protective surface protein from type V group B streptococci shares N-terminal sequence homology with the alpha C protein.
    Lachenauer CS, Madoff LC.
    Infect Immun; 1996 Oct 13; 64(10):4255-60. PubMed ID: 8926097
    [Abstract] [Full Text] [Related]

  • 32. Passive protection of mice against group A streptococcal pharyngeal infection by lipoteichoic acid.
    Dale JB, Baird RW, Courtney HS, Hasty DL, Bronze MS.
    J Infect Dis; 1994 Feb 13; 169(2):319-23. PubMed ID: 8106764
    [Abstract] [Full Text] [Related]

  • 33. Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine.
    Larsson C, Stålhammar-Carlemalm M, Lindahl G.
    Vaccine; 1999 Feb 05; 17(5):454-8. PubMed ID: 10073723
    [Abstract] [Full Text] [Related]

  • 34. Immunoprecipitation and opsonic cross-reaction between type-14 pneumococcus and group-B streptococcus type III.
    Fischer GW, Lowell GH, Crumrine MH, Wilson SR.
    Lancet; 1979 Jan 05; 1(8107):75-7. PubMed ID: 84130
    [Abstract] [Full Text] [Related]

  • 35. Group B streptococcal surface proteins as targets for protective antibodies: identification of two novel proteins in strains of serotype V.
    Areschoug T, Stålhammar-Carlemalm M, Larsson C, Lindahl G.
    Infect Immun; 1999 Dec 05; 67(12):6350-7. PubMed ID: 10569749
    [Abstract] [Full Text] [Related]

  • 36. The putative R1 protein of Streptococcus agalactiae as serotype marker and target of protective antibodies.
    Moyo SR, Maeland JA, Lyng RV.
    APMIS; 2001 Dec 05; 109(12):842-8. PubMed ID: 11846725
    [Abstract] [Full Text] [Related]

  • 37. Cross protection in mice with the Smith diffuse stain of Staphylococcus aureus versus a type Ia strain of group B streptococci.
    Ichiman Y, Yoshida K.
    Can J Microbiol; 1982 Jul 05; 28(7):726-32. PubMed ID: 6756624
    [Abstract] [Full Text] [Related]

  • 38. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes.
    Madoff LC, Paoletti LC, Tai JY, Kasper DL.
    J Clin Invest; 1994 Jul 05; 94(1):286-92. PubMed ID: 7518832
    [Abstract] [Full Text] [Related]

  • 39. Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity.
    Seepersaud R, Hanniffy SB, Mayne P, Sizer P, Le Page R, Wells JM.
    Infect Immun; 2005 Mar 05; 73(3):1671-83. PubMed ID: 15731068
    [Abstract] [Full Text] [Related]

  • 40. Vaccination with highly purified cell surface proteins confers protection against experimental group B streptococcal infection.
    Larsson C, Stålhammar-Carlemalm M, Lindahl G.
    Adv Exp Med Biol; 1997 Mar 05; 418():851-3. PubMed ID: 9331786
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.